Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Cell-Based Biological Reagents Global Market Report 2026-2030 | Capitalize on 8.6% CAGR | Thermo Fisher, Merck, Danaher and Lonza Lead the Industry

Thermo Fisher Scientific Inc.

Dublin, Oct. 21, 2026 -- "Cell-based Biological Reagents Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global cell-based biological reagents market is projected to grow from $13.78 billion in 2025 to $14.93 billion in 2026, representing a compound annual growth rate (CAGR) of 8.3%. By 2030, the market is expected to reach $20.74 billion, expanding at a CAGR of 8.6% during the forecast period.

Historical market growth has been supported by the expansion of drug discovery programs, increased pharmaceutical research and development spending, wider use of cell-based assays in toxicity testing, advances in cell culture technologies, and growing adoption of standardized biological reagents. These factors have strengthened demand for reliable cell lines, assay kits, culture products, and related research tools across pharmaceutical, biotechnology, academic, diagnostic, and contract research settings.

Growth through 2030 will be driven by rising demand for predictive in vitro models, expanding personalized medicine research, increased use of artificial intelligence in drug screening, and greater investment in regenerative medicine. Research organizations are also prioritizing complex disease models that more closely reproduce human biology, supporting the adoption of three-dimensional cell culture systems, gene-edited cell lines, reporter cell lines, stem cells, primary cells, and high-throughput screening platforms.

The increasing focus on cell and gene therapies is a major catalyst for the cell-based biological reagents market. These advanced therapies require dependable materials and workflows for the culture, modification, characterization, and delivery of therapeutic cells and genetic material. Demand is rising as developers pursue treatments for rare, inherited, and chronic diseases that may be addressed at the cellular or genetic level. According to IQVIA Holdings Inc., global spending on cell and gene therapies reached $5.9 billion in 2023, an increase of 38% compared with 2022. Continued investment in these therapeutic areas is expected to increase demand for specialized biological reagents throughout discovery, preclinical development, manufacturing, and quality assessment.

Product innovation is increasingly centered on human-induced pluripotent stem cell research, advanced organoid models, targeted cell differentiation, and human-specific testing systems. In July 2024, BioServe Biotechnologies (India) Private Limited introduced an advanced stem cell product line designed to support regenerative medicine and drug development. The portfolio incorporates iPSC generation, three-dimensional organoid culture, and targeted differentiation capabilities intended to reduce experimental variability. Such platforms can improve toxicity assessment, support disease modeling, reduce reliance on animal testing, and help researchers evaluate potential therapies using biologically relevant human models.

Strategic acquisitions are also reshaping the competitive landscape. In April 2023, AnaBios Corporation acquired Cell Systems Inc. for an undisclosed amount. The transaction expanded AnaBios' portfolio of human tissue products, primary cells, cell culture media, and cell-based reagents. The combined capabilities are intended to provide pharmaceutical, biotechnology, and academic researchers with more biologically relevant tools for drug discovery and translational research.

Tariffs present a notable challenge by increasing the cost of imported cell culture media, growth factors, assay kits, laboratory consumables, and advanced cell-processing equipment. Pharmaceutical and biotechnology organizations in North America and Europe are particularly exposed to imported reagent costs, while suppliers in Asia-Pacific face pressure on export pricing. These conditions are influencing procurement strategies and raising research expenses. At the same time, trade pressures are encouraging local reagent manufacturing, regional supplier development, supply-chain diversification, and investment in domestic life science production capacity.

Overall, the cell-based biological reagents market outlook remains strong. Expanding cell and gene therapy pipelines, more sophisticated human disease models, high-throughput drug screening, stem cell research, and demand for physiologically relevant testing platforms are expected to create sustained opportunities for reagent developers, research institutions, biotechnology companies, and pharmaceutical manufacturers through 2030.

Markets Covered:
1) By Product Type: Assay Kits; Cell Lines; Reagents; Other Product Types
2) By Technology: Two Dimensional Cell Culture; Three Dimensional Cell Culture; High Throughput Screening Platforms; Stem Cell Technologies; Gene Edited Cell Platforms
3) By Application: Drug Discovery and Development; Toxicology and Safety Assessment; Disease Modeling; Regenerative Medicine; Basic Research
4) By End User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Contract Research Organizations; Clinical and Diagnostic Laboratories; Government and Public Health Agencies

Subsegments:
1) By Assay Kits: Cell Viability Assay Kits; Cytotoxicity Assay Kits; Proliferation Assay Kits; Apoptosis Assay Kits; Signal Transduction Assay Kits
2) By Cell Lines: Primary Cell Lines; Immortalized Cell Lines; Stem Cell Lines; Cancer Cell Lines; Transfected Cell Lines
3) By Reagents: Culture Media Reagents; Growth Factor Reagents; Enzyme Reagents; Supplement Reagents; Antibody Reagents
4) By Other Product Types: Cryopreservation Reagents; Labware Consumables; Transfection Reagents; Cell Sorting Reagents; Custom Reagents

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Report AttributeDetails
No. of Pages250
Forecast Period2026-2030
Estimated Market Value (USD) in 2026$14.93 Billion
Forecasted Market Value (USD) by 2030$20.74 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal

The companies featured in this Cell-based Biological Reagents market report include:

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • FUJIFILM Corp.
  • Danaher Corporation
  • GE Healthcare
  • Becton
  • Dickinson And Company
  • Corning Incorporated
  • Lonza Group Ltd.
  • Agilent Technologies Inc.
  • Sartorius AG
  • Revvity Inc.
  • Bio-Rad Laboratories Inc.
  • STEMCELL Technologies Inc.
  • Miltenyi Biotec
  • Abcam plc
  • Promega Corporation
  • Takara Bio Inc.
  • R&D Systems Inc.
  • MP Biomedicals
  • Sino Biological
  • Cell Signaling Technology Inc.
  • InvivoGen
  • Tocris Bioscience
  • OPM Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/1rcmc1

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. AIGlobal Bioprocessing Reagent Market Report 2026 | Capitalize on 12.3% CAGR as Thermo Fisher, Danaher, Merck KGaA and Sartorius Accelerate AI and Single-Use SystemsCompanies: Thermo Fisher Scientific Inc.Danaher CorporationMerck KGaABoost ROI via single-use systems, AI optimization and continuous processing to cut capital costs, contamination and downtime while improving yield, scalability and efficiency.
  2. Biotech & pharmaGlobal Bioprocessing Support Services Market Report 2026 | Capitalize on $4.13B by 2030 as Thermo Fisher, Merck, Sartorius and Samsung Biologics Scale Single-Use SolutionsCompanies: Thermo Fisher Scientific Inc.Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production.
  3. Global Cell Culture Media and Single-Use Reagents Market Report 2026 | Capitalize on 13.6% CAGR to $8.34B by 2030 with Thermo Fisher, Merck, Sartorius and LonzaCompanies: Thermo Fisher Scientific Inc.Boost ROI with integrated single-use bioreactors that reduce contamination, setup time, cleaning, footprint and operating costs while improving scalability.
  4. Upstream Bioprocessing Equipment Market Report 2026: Forecast to 2030 | Accelerate Single-Use Scale-Up as Thermo Fisher, Merck, Danaher, Sartorius and Repligen Drive 10.9% CAGRCompanies: Thermo Fisher Scientific Inc.Danaher Corporation"Upstream Bioprocessing Equipment Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  5. Biotech & pharmaBioconjugation Market Report 2026: Global Size, Share, Trends and 2030 Forecast | Capitalize on Targeted Therapeutics | Thermo Fisher, Merck, Danaher, Lonza, and Agilent Lead the IndustryCompanies: Thermo Fisher Scientific Inc.Agilent TechnologiesDanaher Corporation"Bioconjugation Market Report 2026" has been added to ResearchAndMarkets.com's offering.
  6. FinanceGlobal Human Osteoblasts Market Report 2026 | Capitalize on $53.09 Billion Revenue Share by 2030 as Merck KGaA, Thermo Fisher Scientific, Lonza and STEMCELL Lead the IndustryCompanies: Merck KGaAThermo Fisher Scientific Inc."Human Osteoblasts Market Report 2026" has been added to ResearchAndMarkets.com's offering.